Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04331535 | The Genomic Medicine at VA Study(GenoVA) | unknown | N/A | 1,076 | Boston VA Research Institute, Inc.OTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05038657 | Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).(AURORA) | unknown | Phase 2 | 36 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Oct 3, 2022 |
| clinicaltrials |
| NCT05561413 | Gynaecology Exercise and Mindfulness Study(GEMS) | unknown | N/A | 40 | University of UlsterOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04239599 | Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate Cancer(RCT-PHART2) | unknown | N/A | 178 | Sunnybrook Health Sciences CentreOTHER | 0 | Sep 29, 2022 | clinicaltrials |
| NCT05560035 | The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery | unknown | N/A | 60 | General Hospital of Ningxia Medical UniversityOTHER | 0 | Sep 29, 2022 | clinicaltrials |
| NCT04245670 | 5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:(5STAR-PC) | unknown | N/A | 75 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05557565 | A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | unknown | Phase 2 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT01197625 | Vaccine Therapy in Curative Resected Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT03278717 | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients(ICON9) | unknown | Phase 3 | 330 | University College, LondonOTHER | 4 | Sep 27, 2022 | clinicaltrials |
| NCT05537844 | Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma(BriTROC-2) | unknown | — | 250 | Liz-Anne LewsleyOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT04913025 | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers(REFINE) | unknown | Phase 2 | 160 | University College, LondonOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05458973 | Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation. | unknown | — | 100 | Yonsei UniversityOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05532930 | An Exploratory Study of Using Magnetic Resonance Prognostic Imaging Markers for Radiotherapy In Patients With Cervix Cancer (EMPIRIC Study)(EMPIRIC) | unknown | — | 40 | East and North Hertfordshire NHS TrustOTHER_GOV | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05522907 | Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer | unknown | — | 1,000 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05523804 | Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer(GO SOAR2) | unknown | — | 800 | NHS GrampianOTHER_GOV | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04262427 | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma(CAPER) | unknown | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05512663 | Safety and Efficacy Evaluation of Transperineal Irreversible Electroporation (IRE) of Anterior Prostate Cancer | unknown | N/A | 10 | Jewish General HospitalOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT04015739 | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse(BOLD) | unknown | Phase 2 | 74 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05440045 | A Clinical Study of 6MW3211 in Patients With Renal Cancer | unknown | Phase 2 | 30 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Aug 17, 2022 | clinicaltrials |
| NCT05243173 | Biomarkers of Response to Systemic Treatments in FH-deficient RCC | unknown | — | 100 | RenJi HospitalOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05503563 | A Proposed Tetra-modal Treatment Protocol for Muscle Invasive Urothelial Carcinoma of the Urinary Bladder | unknown | — | 50 | Assiut UniversityOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05043402 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 400 | OncXerna Theraputics, Inc.INDUSTRY | 0 | Aug 15, 2022 | clinicaltrials |
| NCT03844256 | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study(CRIMI) | unknown | Phase 1 / Phase 2 | 50 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05496517 | Ovarian Cancer Individualized Scoring System Scoring System(OCISS) | unknown | — | 1,000 | Assiut UniversityOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05285319 | Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer | unknown | Phase 2 | 82 | Cairo UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04641728 | Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer | unknown | Phase 2 | 28 | Saitama Medical University International Medical CenterOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04796467 | 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients | unknown | Phase 2 / Phase 3 | 50 | Peking Union Medical College HospitalOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05258526 | Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study)(BENEFIT-CA) | unknown | N/A | 80 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05493319 | Hypopressive Exercise Associated With Strength and Resistance Training in Women Treated for Gynecological Cancer | unknown | N/A | 36 | Universidade Federal de Sao CarlosOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04282876 | Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer | unknown | — | 60 | Aarhus University HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05485883 | Tislelizumab Plus Lenvatinib in Stage III-IV RCC(TILUR) | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05486871 | Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study. | unknown | N/A | 30 | Sohag UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05488353 | A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma | unknown | Phase 4 | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 4, 2022 | clinicaltrials |
| NCT04995731 | Risk Assessment of Endometrial Hyperplasia and Endometrial Cancer | unknown | — | 328 | Assiut UniversityOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05481372 | PINPOINT Feasibility Study | unknown | N/A | 14 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05017181 | Novel MRI Assessment of Prostate Cancer VALIDATE-PRO(VALIDATE-PRO) | unknown | — | 234 | University College, LondonOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05139134 | Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05179317 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05479487 | Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | unknown | Phase 2 | 132 | Xiaohua Wu MDOTHER | 0 | Jul 29, 2022 | clinicaltrials |
| NCT04903665 | PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I | unknown | — | 495 | Fudan UniversityOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05475847 | Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer(TIL) | unknown | Phase 1 | 20 | Fudan UniversityOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT02562365 | Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer(ACTS) | unknown | Phase 2 | 130 | Xiaohua Wu MDOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT04845425 | Analysis of miRNA Expression in Endometrial Cancer(MIRCE) | unknown | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05467319 | Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS(FORGE) | unknown | Phase 3 | 82 | Alberta Health Services, CalgaryOTHER | 0 | Jul 20, 2022 | clinicaltrials |
| NCT04839029 | Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT | unknown | N/A | 200 | Benha UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04996602 | Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 3, 2022source: clinicaltrials